Incidence and correlates of tardive dyskinesia in first episode of schizophrenia

Archives of General Psychiatry

Volumn 53, Issue 4, 1996, Pages 313-319

  Chakos, Miranda H ^a   Alvir, Jose Ma J ^a   Woerner, Margaret G ^a   Koreen, Amy ^a   Geisler, Stephen ^a   Mayerhoff, David ^a   Sobel, Steven ^a   Kane, John M ^a   Borenstein, Michael ^a   Lieberman, Jeffrey A ^a,b  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BENZATROPINE MESILATE; CLOZAPINE; FLUPHENAZINE; HALOPERIDOL; LORAZEPAM; MOLINDONE; NEUROLEPTIC AGENT; PROPRANOLOL;

ADULT; ARTICLE; DRUG INDUCED DISEASE; EXTRAPYRAMIDAL SYMPTOM; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; NEUROTOXICITY; PROSPECTIVE STUDY; PSYCHOPHARMACOTHERAPY; PSYCHOSIS; SCHIZOPHRENIA; TARDIVE DYSKINESIA; TREATMENT OUTCOME;

EID: 15844410325     PISSN: 0003990X     EISSN: None     Source Type: Journal    
DOI: 10.1001/archpsyc.1996.01830040049009     Document Type: Article

References (49)

1. Jeste DV. Epidemiology. In: Jeste DV, Wyatt RJ, eds. Understanding and Treating Tardive Dyskinesia. New York, NY: Guilford Press; 1982:10-38.
2. Woerner, MG, Kane JM, Lieberman JA, Alvir JM, Bergmann KJ, Borenstein M, Schooler NR, Mukherjee S, Rotrosen J, Rubinstein M, Basavaraju N. The prevalence of tardive dyskinesia. J Clin Psychopharmacol. 1991;11:34-42.
3. Jeste DV, Wyatt RJ Changing epidemiology of tardive dyskinesia. an overview. Am J Psychiatry. 1981;138.297-309.
4. Kane JM, Smith JM. Tardive dyskinesia: prevalence and risk factors, 1959 to 1979. Arch Gen Psychiatry. 1982;39:473-481.
5. Kane JM, Woerner M, Borenstein M, Wegner J, Lieberman J. Integrating incidence and prevalence of tardive dyskinesia. Psychopharmacol Bull. 1986;22: 254-258.
6. Morgenstern H, Glazer WM. Identifying risk factors for tardive dyskinesia among long-term outpatients maintained with neuroleptic medications. Arch Gen Psychiatry. 1993;50:723-733.
7. Kane JM, Woerner M, Lieberman JA, Kinon BJ Tardive dyskinesia: prevalence, incidence and risk factors J Clin Psychopharmacol. 1988;8:259-262.
8. Saltz BL, Woerner MS, Kane JM, Lieberman JA, Alvir JMJ, Bergmann KJ, Blank K, Koblenzer J, Kahaner K. Prospective study of tardive dyskinesia incidence in the elderly. JAMA 1991;266.2402-2406.
9. Jeste DV, Caligiun MP, Paulsen JS, Heaton RK, Lacro JP, Harris MJ, Bailey A. Fell RL, McAdams LA. Risk of tardive dyskinesia in older patients: a prospective longitudinal study of 266 outpatients Arch Gen Psychiatry. 1995;52:756-765
10. Casey DE. Tardive dyskinesia and affective disorders. In: Casey DE, ed. Tardive Dyskinesia and Neuroleptics: From Dogma to Reason Washington, DC. American Psychiatric Press; 1985:1-20.
11. Woerner MG, Saltz BL, Kane JM, Liebermann JA, Alvir JMJ Diabetes and development of tardive dyskinesia Am J Psychiatry 1993;150:966-968.
12. Yassa R, Ghadinan AM, Schwartz G. Prevalence of tardive dyskinesia in affective disorder patients. J Clin Psychiatry. 1983;44:410-412.
13. Owens DG, Johnstone EC. The disabilities of chronic schizophrenia: their nature and the factors contributing to their development. Br J Psychiatry. 1980; 136-384-395.
14. Owens DG, Johnstone EC, Frith CD. Spontaneous involuntary disorders of movement Arch Gen Psychiatry 1982;39:452-461
15. Kane JM, Woerner M, Sarantakos S, Kinon B, Lieberman J Do low dose neuroleptics prevent or ameliorate tardive dyskinesia? In: Casey DE, ed. Tardive Dyskinesia and Neuroleptics: From Dogma to Reason. Washington. DC: American Psychiatric Press, 1985-99-108.
16. Kane JM, Rifkin A, Woerner M. Low-dose neuroleptic treatment of outpatient schizophrenics. Arch Gen Psychiatry. 1983;40:893-896.
17. Chatterjee A, Chakos M, Koreen A, Geisler S, Sheitman B, Alvir J, Lieberman JA. Prevalence and clinical correlates of extrapyramidal signs and spontaneous dyskinesias in never medicated schizophrenic patients Am J Psychiatry. 1995;152:1724-1729.
18. Lieberman JA, Jody D, Alvir JMJ, Ashtari M, Levy D, Bogerts B, Degreef G, Mayerhoff D, Cooper T. Brain morphology, dopamine and eye-tracking abnormalities in first-episode schizophrenia: prevalence and clinical correlates Arch Gen Psychiatry. 1993;50:357-368.
19. Lieberman J, Jody D, Geisler S, Alvir J, Loebel A, Szymanski S, Woerner M, Borenstein M. Time course and biologic correlates of treatment response in first-episode schizophrenia. Arch Gen Psychiatry. 1993;50.369-376.
20. Endicott J, Spitzer RI A diagnostic interview: the Schedule for Affective Disorders and Schizophrenia. Arch Gen Psychiatry. 1978,35:837-844.
21. Spitzer RL, Endicott J, Robins E Research Diagnostic Criteria. Arch Gen Psychiatry 1978;35:773-782.
22. Spitzer RL, Endicott J. Schedule for Affective Disorders and SchizophreniaChange Version. 3rd ed New York: New York State Psychiatric Institute; 1978
23. National Institute of Mental Health. Rating scales and assessment instruments for use in pediatric psychopharmacology research. Psychopharmacol Bull. 1985; 21:839-844.
24. Endicott J, Spitzer RI, Fleiss JD, Cohen J. The Global Assessment Scale: a procedure for measuring overall severity of psychiatric disturbance. Arch Gen Psychiatry 1976;33:766-771.
25. Simpson GM, Lee JH, Zoubek B, Gardos G. A rating scale for tardive dyskinesia. Psychopharmacology. 1979;64:171-179.
26. Simpson GM, Angus JWS. A rating scale for extrapyramidal side effects Acta Psychiatr Scand Suppl. 1970,212:1-58.
27. Andreasen NC, Olsen S. Negative vs positive schizophrenia: definition and validation. Arch Gen Psychiatry 1982;39 789-794.
28. Cannon-Spoor HE, Potkin SG, Wyatt RJ. Measurement of premorbid adjustment in chronic schizophrenia. Schizophr Bull 1982,8:470-484.
29. Guy W Abnormal Involuntary Movement Scale. In: ECDEU Assessment Manual for Psychopharmacology. Washington, DC: US Public Hearth Service, 1976. 534-537.
30. Schooler NR, Kane JM. Research diagnoses for tardive dyskinesia. Arch Gen Psychiatry. 1982;39:486-487.
31. Muscettola G, Pampallona S, Barbato G, Casiello M, Bollini P. Persistent tardive dyskinesia: demographic and pharmacological risk factors. Acta Psychiatr Scand 1993;87 29-36.
32. Cavallaro R, Regazzetti MG, Mundo E, Brancato V, Smeraldi E. Tardive dyskinesia outcomes: clinical and pharmacologic correlates of remission and persistence. Neuropsychopharmacology. 1993;8:233-239.
33. Thomas P, McGuire R. Orofacial dyskinesia, cognitive function and medication. Br J Psychiatry. 1986;149216-220.
34. Chouinard B, Annable L, Ross-Chouinard A, Nestoros JN. Factors related to tardive dyskinesia. Am J Psychiatry. 1979;136.79-83.
35. Lieberman JA, Alvir J, Geisler S, Ramos-Lorenzi J, Woerner M, Novacenko H, Cooper T, Kane JM. Methylphenidate response, psychopathology and tardive dyskinesia as predictors of relapse in schizophrenia. Neuropsychopharmacology. 1994;11:107-118.
36. Richardson MA, Pass R, Bregman Z. Contrasts between patients' characteristics associated with tardive dyskinesia versus those associated with parkinsonismlike symptoms In: Wolf ME, Mosnaim AD, eds. Tardive Dyskinesia: Biological Mechanisms and Clinical Aspects. Washington, DC: American Psychiatric Press; 1988.107-122.
37. Waddington JL, Hanafy AY, Dolhin C, Kinesella A. Cognitive dysfunction, negative symptoms, and tardive dyskinesia in schizophrenia. Arch Gen Psychiatry. 1987;44 907-912.
38. Waddington JL, O'Callaghan E, Larken D Cognitive dysfunction in schizophrenia: organic vulnerability factor or state marker for tardive dyskinesia. Brain Cogn 1993;23:56-70.
39. Wegner JT, Catalano F, Gibralter J, Kane JM. Schizophrenics with tardive dyskinesia-neuropsycholagical deficit and family psychopathology. Arch Gen Psychiatry. 1985;42:860-865.
40. Liddle PF, Barnes TRE, Speller J, Kibel D. Negative symptoms as a risk factor for tardive dyskinesia in schizophrenia. Br J Psychiatry. 1993;163776-780.
41. Wegner JT, Kane JM, Weinhold P, Woemer M, Kinon B, Lieberman J, Cognitive impairment in tardive dyskinesia. Psychiatry Res. 1985;16:331-337.
42. Crow TJ, Owens DGC, Johnstone ED, Cross AJ, Owen F. Does tardive dyskinesia exist? In: Ban TA, Pichot P, Poldinger LW, St Gallen W, eds. Modern Problems in Pharmacology. Basel, Switzerland: Karger; 1983:206-219.
43. Lieberman JA, Kinon BJ, Loebel AD Dopaminergic mechanisms of idiopathic and drug induced psychosis. Schizophr Bull. 1990;16:97-110.
44. Olney JW, Farber NB Glutamate receptor dysfunction and schizophrenia. Arch Gen Psychiatry. 1995;52:998-1007.
45. Coyle J. Glutamate, oxidative stress and schizophrenia. Presented at the International Congress on Schizophrenia Research; April 10, 1995; Hot Springs, Va.
46. Chakos MH, Mayerhoff DI, Loebel AD, Alvir JM, Lieberman JA. Incidence and correlates of acute extrapyramidal symptoms in first episode schizophrenia. Psychopharmacol Bull. 1992;28:81-86.
47. Chakos MH, Lieberman JA, Bilder RM, Lerner G, Bogerts B, Degreef G, Wu H, Ashtari M. Increase in caudate nuclei volumes of first episode schizophrenic patients taking antipsychotic drugs. Am J Psychiatry. 1994;151:1430-1436.
48. Kowlakowska T, William AO, Ardern M, Reveley MA. Tardive dyskinesia in schizophrenics under 60 years of age. Biol Psychiatry. 1986;21:161-169.
49. Glazer WM, Morgenstern H, Doucette J. Race and tardive dyskinesia among outpatients at a CMHC. Hosp Community Psychiatry 1994,45 38-42